Novan Presents Preclinical Data from Inflammatory Skin Diseases Program
Poster Presentations Provide Mechanistic Evidence for SB414 as a Potential Treatment for Psoriasis and Atopic Dermatitis
Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from two preclinical studies with SB414, a nitric oxide-releasing cream in development for the treatment of inflammatory skin diseases such as psoriasis and atopic dermatitis, will be presented at the 76th Annual Meeting of the Society for Investigative Dermatology in Portland, Oregon. In a psoriasis mouse model, SB414 significantly (p<0.05) reduced composite psoriasis scores and also inhibited the production of pro-inflammatory cytokines, including interleukin-17, or IL-17a and IL-17f. Additionally, in two in vivo models that assess critical components of atopic dermatitis disease pathology, SB414 displayed potent anti-staphylococcal activity and dose-dependent inhibition of inflammation comparable to betamethasone, a mid-potency corticosteroid used to treat eczema patients.